Severe calcified aortic stenosis (AS) is an important long-term complication of homozygous FH (HoFH). However, it is unclear whether the introduction of statins has affected the AS phenotype in patients with HoFH. This systematic review provides more insight.

Using data from the CANTOS trial, the investigators assessed the relative contributions of hyperlipidemia and inflammation to CV clinical outcomes in atherosclerosis patients on statin therapy, stratified by eGFR.

EASD 2022 "Any patient that has HFmrEF or HFpEF is going to benefit from dapaglifozin regardless of glycemic status and regardless of background diabetes therapy", says Prof. Jhund.

EASD 2022 A prespecified secondary analysis was performed to investigate whether muscle fat infiltration -associated with increased risk of HF- can be modified by treatment with liraglutide in patients with overweight or obesity.

EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.

The European Heart Journal has published the 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.

EASD 2022 A post hoc analysis of the STEP 5 trial showed that a greater proportion of adults with overweight achieved remission of metabolic syndrome and a smaller proportion developed metabolic syndrome with semaglutide vs. placebo.

EASD 2022 It is useful to know whether sodium and protein intake affect the early GFR dip that may be observed after initiation with SGLT2i, says Marta Seghieri. She shares the findings of a pilot study.

EASD 2022 It is not known whether a higher intake of sodium and protein may lead to a higher extent of early dip in GFR in T2DM patients who started an SGLT2 inhibitor. A pilot study was undertaken with 28 subjects.

EASD 2022 A post hoc analysis showed that semaglutide reduces CV risk across all strata of kidney function and kidney damage in patients with T2DM who are at high CV risk.

EASD 2022 This pooled post hoc analysis of SUSTAIN 6 and PIONEER 6 showed that that semaglutide consistently reduced the risk of MACE across eGFR and UACR subgroups in patients with T2DM who are at high CV risk.

EASD 2022 In patients with new onset T2DM in the DD2 cohort, high CRP was a better marker of all-cause mortality than future CV events, whereas high C-peptide was a better marker of increased CV risk.